Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7485481 | 0.92 | ADORA1 (0.52) | ADORA1IGF1RMAPK1AKT1MAPK3 | |
| SCHEMBL7488103 | 0.91 | ADORA1 (0.52) | ADORA1IGF1RMAPK1AKT1EGFR | |
| SCHEMBL7490771 | 0.90 | ADORA1 (0.52) | ADORA1IGF1RMAPK1EGFR | |
| SCHEMBL7495433 | 0.89 | ADORA1 (0.50) | ADORA1IGF1RMAPK1AKT1DRD2 | |
| SCHEMBL7485492 | 0.89 | ADORA1 (0.51) | ADORA1IGF1RMAPK1EGFR | |
| SCHEMBL7487498 | 0.89 | ADORA1 (0.53) | ADORA1IGF1RMAPK1AKT1MAPK3 | |
| Hydrochloric Acid SCHEMBL7541956 | 0.88 | ADORA1 (0.52) | ADORA1IGF1RMAPK1AKT1MAPK3 | |
| SCHEMBL7496245 | 0.86 | ADORA1 (0.48) | ADORA1IGF1RMAPK1AKT1MAPK3 | |
| SCHEMBL7668541 | 0.86 | ADORA1 (0.53) | ADORA1IGF1RMAPK1AKT1MAPK3 | |
| SCHEMBL7487132 | 0.85 | ADORA1 (0.52) | ADORA1IGF1RMAPK1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | The united States of America,as represented by Secretary,Dept.,of Health and Human Services (US) | 2013-05-02 | — | — | US | disclosed |
| EP-0925299-B1 | PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6124456-A | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109645-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE TREATMENT AND PREVENTION OF VASCULAR OR JOINT CAPSULE CALCIFICATION DISORDERS | NT5E, NT5C2, NT5C3B | ADORA1 9/4885IGF1R 1542/4885MAPK1 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.